成人肾移植受者CYP3A5基因型指导的他克莫司给药方案实施
该文描述了在学术医疗中心为成人肾移植受者实施CYP3A5基因型指导的他克莫司给药方案的过程。
要点
- 成人肾移植受者因口服他克莫司且药物相互作用有限被选为目标人群。
- 实施需评估检测实验室的变异覆盖、周转时间、成本和结果返回流程。
- 临床决策支持可自动选择移植后初始他克莫司剂量。
核心结论
- 整合药物基因组学到他克莫司给药方案在多学科支持下是可行的。
研究设计与样本
- 描述在学术医疗中心实施CYP3A5基因型指导他克莫司给药方案的过程。
主要发现
- 实施后多数(61%)成人肾移植受者接受了基因型指导给药。
临床怎么用
- 移植前检测需开发多种工作流程以覆盖登记或等待名单及面对面和虚拟照护的患者。
- 临床决策支持可自动选择移植后初始他克莫司剂量。
- clinician教育根据个人在实施过程中的角色定制,并开发患者教育。
局限性
- 未来研究将评估该给药策略对临床和医疗利用结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite a well-established association of CYP3A5 genotype with tacrolimus dose requirements and clinical practice guidelines for personalized dosing, integration of genotype-guided tacrolimus dosing is limited. Herein we describe the process for implementing a CYP3A5 genotype-guided tacrolimus dosing protocol in adult kidney transplant recipients at an academic medical center. SUMMARY: We evaluated existing primary literature and clinical practice guidelines, as well as internal data, to determine the target population for implementation. Adult kidney transplant recipients were selected given the routine use of oral tacrolimus and limited drug-drug interactions. These data were also used to gain prescriber buy-in for and determine genotype-guided tacrolimus dose recommendations. Selecting a testing laboratory involved assessment of variant coverage, turnaround time, cost, and the return process for results. Obtaining testing before transplantation required development of multiple workflows to capture patients at listing or on the waitlist and for in-person and virtual care. Clinical decision support to automatically select initial post-transplantation tacrolimus doses per the genotype-guided protocol was developed. Clinician education was tailored to the role the individual had in the implementation process, and patient education was developed. Genotype-guided dosing was implemented in October 2023, approximately 1 year after conceptualization. The majority (61%) of adult kidney transplant recipients since implementation have received genotype-guided dosing. CONCLUSION: Implementation of CYP3A5 genotype-guided tacrolimus dosing requires unique considerations associated with route of administration and transplant population, but integrating pharmacogenetics into a tacrolimus dosing protocol is feasible with multidisciplinary support. Future studies will evaluate the impact of this dosing strategy on clinical and healthcare utilization outcomes.
引用
- Pasternak AL, Zimmerman C, Park JM, et al. Establishing a CYP3A5 genotype-guided tacrolimus dosing protocol in adult kidney transplant recipients. Am J Health Syst Pharm. 2026. PMID: 40823719. doi:10.1093/ajhp/zxaf215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。